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Abstract: The longitudinal effect of an anti-vascular endothelial growth factor receptor 2
(VEGFR-2) antibody (DC 101) therapy on a xenografted renal cell carcinoma (RCC) mouse
model was monitored using hybrid diffuse optics. Two groups of immunosuppressed male nude
mice (seven treated, seven controls) were measured. Tumor microvascular blood flow, total
hemoglobin concentration and blood oxygenation were investigated as potential biomarkers for the
monitoring of the effect of therapy twice a week and were related to the final treatment outcome.
These hemodynamic biomarkers have shown a clear differentiation between two groups by day
four. Moreover, we have observed that pre-treatment values and early changes in hemodynamics
are highly correlated with the therapeutic outcome demonstrating the potential of diffuse optics
to predict the therapy response at an early time point.
© 2017 Optical Society of America
OCIS codes: (300.6480 ) Spectroscopy, speckle; (170.3890) Medical optics instrumentation; (170.1470) Blood or tissue
constituent monitoring; (170.3660) Light propagation in tissues; (170.6510) Spectroscopy, tissue diagnostics; (110.4234)
Multispectral and hyperspectral imaging.
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1. Introduction
Angiogenesis, the formation of new blood vessels, plays an important role in the growth and
spread of cancer [1–3]. In order to develop angiogenesis, tumors undergo a complex signaling
process by the production of angiogenic agents, one of those is the vascular endothelial growth
factor (VEGF) [4]. As expected, the inhibition of angiogenesis is emerging as a new therapeutic
approach to control tumor progression [5–7].
Angiogenesis inhibitors, alone or in combination with other chemotherapies, are effective in
the treatment of several tumors including renal carcinomas [8–10]. However, the effective period
of these agents is often limited because of the tumor resistance mechanisms [11–15]. In therapies
on human patients, early identification of non-responders is essential to personalize the treatment
and to avoid the resistance phase, which results in more aggressive tumors [16].
Since anti-VEGF agents are expected to inhibit the growth of new blood vessels and starve
rapidly growing tumors of necessary oxygen and blood supply, we (and others) have hypothesized
that local, microvascular oxygenation and blood flow are potentially important biomarkers of
therapy effects. Therefore, in order to improve the outcome of antiangiogenic therapy, a practical
tool for repeated measurements of oxygenation and blood flow to detect the early changes of
these biomarkers is important.
There are several methods to measure the oxygen level in tumors, but due to invasiveness,
depth of measurement, and utilized contrast/radiative agents, these methods are not ideal for
continuous, repeated measurements [17, 18]. For the measurement of the microvascular blood
flow, there are several techniques using exogenous contrast agents (sometimes with ionizing
radiation) and other noninvasive techniques [19] – all with some limitations. Modalities such as
positron emission tomography, dynamic X-ray computed tomography, single-photon emission
computed tomography and magnetic resonance imaging are expensive modalities with limited
applicability and some safety concerns due to utilization of ionized radiation or contrast agents.
Others such as Doppler ultrasound are portable and suitable for repeated measurements but are
often limited to the larger vasculature [20, 21] although emerging technologies are trying to
address this limitation and has been used to image small vessels in rodent brains [22, 23].
Optical methods such as laser Doppler flowmetry and laser speckle flowmetry provide two-
dimensional images of the blood flow in the microvasculature with good spatial resolution (≈5-10
µm). Optical coherence tomography captures micrometer-resolution, three-dimensional images
of tissue structure and blood flow [24–26]. But they are all limited by the low penetration depth
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(sub millimeter) and are suitable for superficial imaging. Considering the limitations of the
current techniques for repeated measurements of deep tissue oxygenation and blood flow, diffuse
optical techniques have gathered significant attention in both pre-clinical and clinical studies.
They have a deeper penetration depth (up to few centimeters) and the penetration depth depends
on the source-detector separation [27].
During the last decade many researchers have demonstrated that diffuse optics is a promising
tool to monitor the hemodynamic changes (in tumors such as breast, head and neck, and
prostrate) induced by cancer therapies such as neoadjuvant chemotherapy, radiation therapy and
photodynamic therapy. These studies have demonstrated the potential of optical monitoring of
tumor hemodynamics to predict therapeutic efficiency [28–39]. In this work, we have investigated
the renal cell carcinoma (RCC), which is not generally sensitive to chemotherapy, so the therapeutic
options are limited. Recent development of targeted treatments has led to a improvement in RCC
treatment outcomes but eventually, all tumors become resistant to anti-VEGF therapies. This
study aims to demonstrate that optics has potential for monitoring anti-VEGF therapy in RCC
tumors for better understanding the anti-VEGF mechanism [40, 41] and predict the outcome. For
this study, we chose to use a hybrid diffuse optics system that measures blood flow by diffuse
correlation spectroscopy (DCS) in addition to tissue oxygenation and hemoglobin concentration
by diffuse optical spectroscopy (DOS) in order to monitor both the supply and demand side of
the hemodynamic changes during antiangiogenic therapy. In principle, this could be extended to
estimate the oxygen metabolism of the tumors which may turn out to be a good biomarker [31].
We have used amurine renal cell carcinoma (RCC)model, originated from humanRCC biopsies
and implanted on immunosuppressed mice. RCC is a highly vascular cancer and antiangiogenic
therapy is the main strategy for its treatment [42, 43]. The VEGFR2 (vascular endothelial growth
factor receptor 2)-blocking antibody (DC101) [44] was applied for treatment as biological and
preclinical evidence suggests that the blockage of VEGFR2 could be a promising strategy to
inhibit tumor-induced angiogenesis [45,46]. We have monitored the tumor hemodynamics before
and during the therapy at regular intervals and related the results to the assessment of the therapy
outcome based on biopsy results.
2. Materials and methods
2.1. Animal models and the treatment procedure
The animal research project protocols for the tumorgraft models have been evaluated and accepted
by IDIBELL’s animal research committee and have been registered and accepted by the “Animal
Experimental Commission” from the local Catalan government and the “Comisión de Ètica en
Experimentación Animal” from the national Spanish government . All animals were purchased
from Harlan Laboratories and were housed and maintained in laminar flow cabinets under specific
pathogen-free conditions.
Orthotopic implantation of renal cell carcinoma (RCC) tumors: The animal models are based
on orthotopic implantation of small pieces (2 x 2 x 2 mm3) of human RCC tumor biopsies
by surgical implantation onto the kidney, the original neoplastic organ, on immunosuppressed
nude mice, following studies pioneered by Dr. G. Capellá [47, 48]. Our samples were renal
cell carcinoma of clear cell histology (REN 28), Fuhrman grade 4/4 and pathological staging
pT3pN1. Fresh surgical specimens of RCC were obtained after surgical resection from the
Hospital Universitari de Bellvitge (L’Hospitalet de Llobregat, Barcelona, Spain) and placed in
Dulbecco’s Modified Eagle’s Medium (DMEM, BioWhittaker), supplemented with 10% FBS
(Fetal bovine serum), 50 units/mL penicillin, and 50 µg/mL streptomycin sulfate. The details of
tumor implantation can be found in Ref [49].
Fourteen immunosuppressed male athymic nude mice of five weeks age weighing 18-22 g
were measured in this study. We have implanted a piece of a human biopsy in one mouse and
let the tumor grow in that animal. The enlarged tumor of the primary mouse was then extracted
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and was cut in equal pieces to be implanted in 14 animals to do this experiment (same tumor
for 14 animals). To minimize the heterogeneity, tumor pieces were cut from the same region
of the original tumor. The process closely mimics the procedure described in Ref. [50]. These
little human tumor biopsies grow in the mice, preserving the stromal architecture. Therefore,
these mouse lines preserve a stromal rich tumor structure in the growing tumors with a good
resemblance to the original human tumor. Thus, these animal models allow for more relevant
studies of the tumor responses to treatment than standard xenograft models. To implant the
tumors, the animals were first anesthetized by isoflurane inhalation then a small midline incision
was made and the kidney was exteriorized. A piece of tumor was implanted on left kidney using
prolene 7-0 surgical suture. The kidney was returned to the abdominal cavity and the incision
was closed with wound clips.
Antiangiogenic treatments: The antiangiogenic drug (DC101) used is very specific monoclonal
antibody that binds and blocks mouse VEGF signaling. This antibody has the advantage of having
a species-restricted activity, as it does neither recognize nor block human-VEGFR2 [51–53].
Therefore, when used in the tumorgraft models, we expect that the drug does not affect the tumor
cells (of human origin) directly but rather only has an antiangiogenic effect [54]. The blocking
antibody of VEGFR2 (DC101) can be obtained in large scale by purification from supernatants of
the hybridoma DC101 in culture (modified from ATCC) and is used at a dose of 1 mg/animal by
intraperitoneal injection as previously described [55,56]. Seven mice received the antiangiogenic
therapy and the rest, control group, placebo (saline). For each mouse when the tumor volume
reached ∼ 1000 mm3 the therapy was started (DC101 or placebo). Day zero is the onset of therapy
(the first injection was at day zero after finishing the optical measurements). All mice were treated
on the same day numbers relative to their respective starting day. The measurement days matched
with the therapy days, which were every 3 or 4 days (day0, day3, day 7, day10 and so on). In all
cases the animals received the therapy few hours after the optical measurements. The mice kept
receiving the therapy/placebo twice per week (1 mg/animal of DC101 or 1 mg/animal of saline
in 200 µl volume) up to the time that due to the tumor size, measured by palpation, or mouse
weight loss, we had to stop the measurement and sacrifice the animal. On average, the control
and treated animals were sacrificed respectively 22.7 ± 4.6 and 29.4 ± 8.6 days after the onset of
the treatment.
Tumor extraction and histologies: After sacrificing each mouse, the tumor was extracted for
the measurement of its volume (by displacement of water in a graduated cylinder) and weight (by
a digital scale), and to prepare it for histological studies. In this study, we have used a cluster of
differentiation 31 (CD31) staining to measure the microvessel density (MVD) in the tumor by
obtaining images of sections using an optical microscope (NIKON-801 DS-Ri1, Tokyo, Japan).
To quantify CD31 staining, five hot spot fields in viable tissue zones at ×400 magnification
were captured for each tumor. Quantification of staining areas was performed using an image
processing program, ImageJ (National Institutes of Health, Maryland, USA), by calculating the
pixels corresponding to vessel areas divided by total number of pixels in the image of the stained
tissue section. The percent necrotic area was also quantified by ImageJ analysis on the digitally
acquired tissue sections stained with hematoxylin and eosin (H&E) by calculating the ratio of
necrotic pixels to the total number of pixels in the image.
2.2. Optical device and data analysis
We have combined broadband near infrared diffuse optical spectroscopy (DOS) [57] and diffuse
correlation spectroscopy (DCS) in a single self-calibrated probe as described below [58].
Broadband near infrared spectroscopy device: A quartz tungsten halogen lamp with maximum
power of 250 W (66499, Newport, CA, USA) was used as the light source. The light was coupled
to a 200 µm multimode fiber to be delivered to the tissue. The detection system consisted of
a 2 dimensional spectrograph (Acton InSight-EFP (1340 × 400 pixels)) and a CCD camera
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(PIXIS:400B-eXcelon (Princeton Instruments)), to image the reflectance spectra from multiple
detection fibers over a wide range of wavelengths simultaneously. The spectrograph contains
a 150 grooves/mm grating with the central wavelength set at 800 nm covering the range of
545-1055 nm. In this study we have considered the data in the range of 610-970 nm.
Diffuse correlation spectroscopy device: DCS uses a single longitudinal mode laser as the
source (CrystaLaser, Reno, NV, USA) at 785 nm whose coherence length is much longer than
the distribution of typical photon path lengths. The laser light is delivered to the tissue through
a multimode fiber with a core diameter of 200 µm (NA = 0.22). DCS uses single mode fibers
of 5.6 µm core diameters for light collection. Four photon counting avalanche photodiodes are
used as detectors (Excelitas Technologies, Waltham, MA, USA) whose output is fed to a digital
correlator (Correlator.com, New Jersey, USA) to obtain the autocorrelation functions. Details of
the DCS system is discussed in various reviews [59–61].
Optical fibers and the probe design: In this study we have deployed two probes: main and
control probe. The main probe (Fiberoptic Systems Inc., Simi Valley, California) consists of both
DOS and DCS fibers. Since the DOS analysis needs calibrated intensity values, the main probe
is designed to be self-calibrating, featuring a miniaturized semicircle scheme for assessing the
source-detector coupling coefficients [58]. There are two DOS sources (Fig. 1), one at the center
of semicircle (calibration source) and the other at in one end of diameter. All nine DOS detectors
are located on the circumference of a semicircle with radius of five millimeters (Fig. 1). The
source in the center of semicircle that has the same distance from all nine DOS detectors which
enables the estimation of the relative coupling coefficients. All DOS source and detector fibers
are multimode fibers (200 µm core). Moreover, the main probe consists of two DCS sources (200
µm core) and seven single-mode fibers for DCS detection, which leads to 14 source-detector
pairs for DCS measurements.
We have not used all the available fibers but rather deployed six source-detector separations for
both DCS and DOS ranging from 1.9 to 5.0 mm. We note that the same optode distances were
used for both DOS and DCS, which allowed us to probe a similar volume with both techniques.
Furthermore, a second, homemade, control probe was also utilized with a single source and
detector distance (4.2 mm) for both DCS and DOS. The control probe was located on a healthy
muscle to catch global hemodynamics alterations during tumor measurements.
Measurement protocol: The optical measurement on each animal was performed on the same
day as therapy induction just few hours prior to the injection of DC101/saline. The animal was
anesthetized during the measurement. The anesthesia was induced by isoflurane induction in
an anesthetic chamber with a 3.5% isoflurane and oxygen mixture with a flow rate of 2 L/min.
After the induction of anesthesia, which was checked by toe pinch, the animal was taken out of
the chamber. Maintenance of anesthesia was administered by means of a nose-cone with 2% of
isoflurane and 1 L/min oxygen flow.
Mouse body temperature was kept constant at around 37◦C using a heating blanket (Homeother-
mic Blanket Systems- Harvard Apparatus). Core body temperature was monitored continuously
during the experiment using a rectal temperature probe to automatically regulate the blanket
temperature.
Each session of optical measurement started by the measurement of the shoulder muscle using
the main probe. The shoulder muscle was measured at four locations on the shoulder to take into
account the variation due to slight probe re-location and at each location, eleven acquisitions
were made. Then, the control probe was fixed on the shoulder using a probe holder and medical
adhesive tape in order to capture probable hemodynamic changes. The tumor was measured by
the main probe using the second probe holder at ten locations and eleven acquisitions per location.
During the tumor measurement, the control probe records the same number of acquisitions as the
main probe; thus for each measurement at the main probe there was a corresponding measurement
of the control probe. At the end of each measurement the shoulder measurement was repeated by
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Only the fibers utilized in
this study are illustrated









Fig. 1. (A) The schematic of hand-held DOS/DCS probe and the way it is applied on the
tumor. The probe schematic only contains the location of the fibers that have been used in
this study. The probe is designed to be self-calibrating, featuring a miniaturized semicircle
scheme for assessing the source-detector coupling coefficients. There is a DOS source in
one end of diameter and also a self-calibration source in the center of semicircle. The DOS
detectors are located on the circumference of this semicircle that makes them equidistant
from the calibration source. (B) An anesthetized nude mouse with a renal tumor and the
optical probes (control and main) on top of the shoulder muscle and tumors with a photograph
of the main probe tip on the top. Since the illuminated light to different fibers was not
homogeneous they have different brightness and visibility. The smaller dots (seven locations)
correspond to single mode fibers (DCS detector fibers). Not all the sources and detectors of
the main probe are used in this study.
the main probe (four locations and eleven acquisitions per location) to confirm that the anesthesia
has not induced considerable changes in the body hemodynamics. The location of the control
probe (shoulder muscle) was roughly 5 cm away from the main probe and at this distance the
light leakage between two probes was negligible. We marked a circle by a waterproof marker on
a small part of shoulder to clarify the control measurement spot (Fig. 1(B)). The measurements
of the shoulder were kept inside the marked area in all measurement sessions. We chose the
shoulder muscle for the control site since it was an easily accessible spot with a chunk of tissue
suitable for diffuse optical measurements that did not interfere with the main tumor measurement.
One complete measurement session for each mouse was about thirty minutes.
2.3. Data analysis
Broadband near infrared spectroscopy analysis: The outputs of the DOS setup are the detected
intensities over wavelength (λ) and source-detector separation (ρ). We go through the following
procedure to obtain concentration of oxy- and deoxy-hemoglobin in in-vivo measurements.
At first, the the wavelength dependent dark noise of each detector was subtracted from the
intensity signal obtained for both calibration (S1) and main source (S2) at each detector fiber
(ith detector). We call this adjusted value of measured intensity from calibration and main
source Ii1m and Ii2m respectively. In the next step the adjusted measured intensities from the main
source at all detectors, Ii2m, were calibrated using the calibration factors deploying the information
obtained from calibration source. To calibrate the system, we need to find the the wavelength
dependent calibration factors for all detectors. We call the calibration factor of ith detector and
jth source Fi
d
(λ) and Fjs(λ) respectively. For calibrating the detectors, we assume one detector as
the reference detector and calibrate the other detectors with respect to that one. In this study, we
chose to calibrate with respect to the first detector and the calibration factor of the first detector is
assumed to be unity (F1
d
(λ) = 1). Assuming a homogenous medium, which is the assumption in
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majority of the multi-distance approaches in the field, all the detectors should represent the same
intensity because they are at the distance from the calibrating source (Ii1 = I11). The calibrated
intensity is calculated as, Ii1 = F1s(λ) × Fid(λ) × Ii1m(λ) = F1s(λ) × F1d(λ) × I11m (λ). Therefore at
each detector the calibration factor can be obtained from Fi
d
(λ) = I11m (λ)
I i1m (λ) . The self-calibration
approach attempts to account for surface inhomogeneities (e.g. a dark spot under a detector fiber).
Moreover, since we do not use a phantom for calibration, we do not need to deal with changes of
coupling coefficient between phantom and tissue. Previous studies have validated the performance
of the self-calibrating probe and broadband continuous wave spectroscopy [58, 62, 63].
The calibrated light intensity, I(ρ, λ), at a distance ρ from the main light source is assumed
to be proportional to the Green’s function solution for diffusion equation in the semi-infinite
boundary condition.
We have assumed a Mie-like model containing a Rayleigh term [64] for the scat-
tering spectrum: A1 and A2) and reduced scattering coefficient is defined as µs ′ =
A1( λλRe f erence )−b + A2( λλRe f erence )−4. The measured absorption coefficients, µa(λ), are related
to the different tissue chromophores as µa(λ) = ∑nci i(λ)ci . The sum is over the different tissue
chromophores. Here we have assumed only water, oxy- and deoxy-hemoglobin as chromophores
(nc = 3). i(λ) is the wavelength-dependent extinction coefficient (Molar absorption coefficient)
of the ith chromophore obtained from the literature: the spectrum of oxy-hemoglobin at 610-800
nm from Ref. [65] and at 800-970 nm from Ref. [66], deoxy-hemoglobin at 610-970 nm from
Ref. [66], and water at 610-970 nm from Ref. [67]. Numerical fitting was done for A1, A2, b and
ci in the wavelength range 610-970 nm for the ratio of the Green’s functions of two fibers at the
same time, G(ci, Aj, b, ρ)/G(ci, Aj, b, ρ0). The DOS analysis relies on the comparison of the ratio
of light between two different separations. This spectrum ratio becomes flatter and more difficult
to fit to if the difference in source-detector separation is small. Therefore, we chose the pairs
with the largest differences in source-detector separation. The three short separations (1.9, 2.5,
and 2.9 mm) were used for ρ0 and the three longest (4.3, 4.6, and 5.0 mm) for ρ. The fitting was
done in Matlab using a nonlinear least square method (LSQNONLIN with Levenberg-Marqardt
algorithm) and the data with poor fitting quality (high residual relative to variance of the signal)
were excluded.
Diffuse correlation spectroscopy analysis: DCS measures the temporal speckle fluctuations of
the scattered light, which is sensitive to the motion of scatterers such as red blood cells which in
turn could be used to estimate microvascular blood flow [59,68,69]. The dynamics of the medium
can be determined by the measurement of the intensity autocorrelation from which the electric
field autocorrelation function can be derived. The semi-infinite homogeneous medium solution to
the correlation diffusion (equation 1) was employed to fit to the measured autocorrelation curves
for a blood flow index (BFI) [59], given by:








Here τ is the delay time, r1 =
√
(1/µs ′)2 + ρ2, rb =
√
(2zb + 1/µs ′)2 + ρ2 and K(τ) =√
3µaµs ′ + 6µs ′2κ2τBFI, where κ is the wave-number of light in the medium and zb is the
extrapolated zero boundary. In this study, for each animal, at each site of measurement (tumor
or muscle), the measured µa and µs ′ at 785 nm by DOS averaged over all locations of each
site (ten locations of tumor and eight locations of muscle) was introduced as inputs for DCS
analysis of its corresponding site. In the fitting, the Nelder-Mead derivative-free simplex method
(“fminsearch”) implemented in Matlab (Mathworks, USA) was used.
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2.4. Statistical analysis
At each measurement session of each mouse the median and interquartile range (IQR) over all
locations (ten tumor locations and eight muscle locations) and acquisitions (11 acquisitions per
location) are reported. The middle line of box plots in Fig. 2 and Fig. 3 indicates the median
value, the top and bottom of each box are the first and third quartile. The dashed lines (whiskers)
are 1.5 times the interquartile range away from the top or bottom of the interquartile lines and
any observations beyond the whisker length are marked as outliers.
The correlation between total hemoglobin concentration and blood flow index (Fig. 4) is
reported by the Pearson product-moment correlation coefficient (R) using “corrcoef” function of
Matlab. The same procedure is used for all reported correlations through this manuscript. In Fig. 5,
the markers and error bars represent the value corresponding to average and standard deviation of
measurements over all tumor locations of each mouse. The average and 95% confidence interval
value of each measurement session over all mice are presented by solid black and gray lines. The
fitted line is calculated by local polynomial regression fitting (“LOESS” package) with a span
value fixed at 0.75 in R (open source statistical computing language [70]).
The difference between distribution of physiological parameters of muscle and tumor is
investigated by a two-tailed t-test (with 95% confidence interval) employing “ttest” function of
“statistics and machine learning toolbox” of Matlab.
To investigate the effect of therapy over time on the tumor volume, BFI, total hemoglobin
concentration (THC), and oxygen saturation (SO2) between the first day and day eighteenth
within animals, which corresponds to the period when no mouse had been sacrificed, a paired
student’s t-test is deployed using “ttest” function of Matlab. Throughout this study, “p-values”
less than 0.05 were considered statistically significant to reject the null hypothesis of distributions
with equal means.
3. Results
3.1. Effect of anti-VEGFR2 treatment on tumor physiology
Figure 2 demonstrates the measured microvessel density (MVD), tumor weight and percent
necrotic area in treated (T1-T7) and control (C1-C7) animals after the therapy period.
Figure 2(A) shows that the median (first-third quartile) value of microvessel density (vessel
count per imaging area unit) in treated animals is 24.6 (14.5- 47.0) and in controls is 62 (55.5-
75.0). Tumors of the treated mice have lower microvessel density in comparison to control group
(P = 0.002).
The measured extracted tumor weight for both treated and control groups are presented in
Fig. 2(B). The median value of extracted tumor weight in treated animals is 1.9 (1.5- 2.5) g and
in controls is 2.7 (2.1- 3.3) g. The extracted tumors from the treated animals are lighter than
control ones (P = 0.034).
Figure 2(C) shows that the percentage of necrotic area in treated and control tumors are
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Fig. 2. The results of histologies retrieved from the extracted tumor after sacrificing the
animal. T1-T7 correspond to values of seven treated animals and C1-C7 corresponds to the
control animals. (A) Microvessel density (MVD) in the extracted tumor measured by CD31
staining. Tumors of treated mice have lower MVD in comparison to control group (P = 0.002).
(B) The extracted tumor weight of treated and control group. The extracted tumors from
the treated animals are lighter than control ones (P = 0.034). (C) The percentage of tumor
necrotic area. There is no statistically significant difference in the tumor percent necrotic area
of treated and control group (P = 0.8). Symbol ~ indicates statistically significant difference
between two groups (treated and control).
3.2. Pre-treatment optical measurements from the tumors
We have measured the wavelength dependent optical properties (µa and µs ′) as well as hemo-
dynamic properties (blood oxygen saturation, total hemoglobin concentration and blood flow
index) of RCC tumors and on the control site (shoulder muscle). The summary of these results is
presented in table 1. For simplicity, we quote the absorption (µa) and the reduced scattering (µs ′)
coefficients at 785 nm since these values were utilized for the BFI calculation measured by DCS.
Table 1 also shows the median and interquartile range of the repeated measurements on different
locations for the pre-treatment values as a measure of tissue heterogeneity at each tissue type. In
this table symbol ~ indicates statistically significant difference between two groups (tumor and
muscle).
The comparison of the pretreatment values of hemodynamic parameters measured on the
tumor and on the control (shoulder muscle) sites shows that the absorption coefficient of the
tumor, 0.19 (0.17- 0.21) cm−1 is lower than the muscle, 0.25 (0.24- 0.27) cm−1 (P = 3 × 10−4)
but there is no significant difference between reduced scattering coefficient of tumor 8.5 (7.5-
9.0) cm−1 and muscle, 9.3 (7.3- 10.5) cm−1 (P = 0.5).
As shown Fig. 3, the median of blood flow index in the tumor 4.5 (4.2- 6.6) ×10−8 cm2/s is
higher than healthy shoulder muscle, 2.3 (2.2- 2.6) ×10−8 cm2/s (P< 10−4). The total hemoglobin
concentration in the tumor, 88.8 (79.3- 97.6) µM, is lower than the healthy shoulder muscle,
111.6 (109.3- 121.0) µM, (P = 8 × 10−4). Blood oxygen saturation of the RCC tumor is 75.1
(72.9- 79.2)%, which is higher than healthy shoulder muscle, 61.5 (58.6- 65.3)%, (P< 10−4).
Figure 4 shows that in both control (C1-C7) and treated (T1-T7) groups the blood flow index
values (measured by DCS) and total hemoglobin concentration (measured by DOS) obtained
over the course of therapy have a positive correlation (Fig. 4). The correlation coefficient for
treated tumors is R = 0.46 (P= 1 × 10−4) and for control tumors is R = 0.44 (P = 1.4 × 10−4).
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Table 1.Median and inter-quartile range pre-treatment (day zero) values of optically measured
parameters on RCC tumors and the control muscle are shown. Furthermore, the median and
inter-quartile range of variability of measured parameters in different locations is also shown
to give an impression of the variability over probe re-locations at a given time point. Symbol
~ indicates a statistically significant difference between two tissue types (tumor and muscle)
Tumor Muscle
Median of all mice Variability in 10 locations Median of all mice Variability in 8 locations
BFI (cm2/s) ~4.5 (4.2- 6.6) ×10−8 1.1 (1.0- 1.9) ×10−8 ~2.3 (2.2- 2.6) ×10−8 0.9 (0.6- 1.5) ×10−8
THC (µM) ~88.8 (79.3- 97.6) 15.2 (11.1- 18.1) ~111.6 (109.3- 121.0) 15.4 (12.8- 17.9)
SO2(%) ~75.1 (72.9- 79.2) 3.4 (2.8- 5.0) ~61.5 (58.6- 65.3) 3.2 (2.1- 3.9)
µa(785 nm)(cm−1) ~0.19 (0.17- 0.21) 0.03 (0.02- 0.04) ~0.25 (0.24- 0.27) 0.03 (0.03- 0.04)
µs

















































Fig. 3. The optically measured pretreatment (day zero) hemodynamic properties of the RCC
tumor in comparison with the control muscle. From left to right: (A) The higher than healthy
shoulder muscle value (P< 10−4). (B) The total hemoglobin concentration in the tumor is
lower than the healthy shoulder muscle (P = 8×10−4). (C) Blood oxygen saturation in the
tumor is higher than healthy shoulder muscle (P< 10−4). Symbol ~ indicates statistically
significant difference between two locations (tumor and muscle).
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Treated mice, R = 0.46, P = 0.0001
Control mice, R = 0.44, P = 0.001
Fig. 4. The measured blood flow index versus total hemoglobin concentration measured
over the course treatment on all mice. The red starts and green circles indicate measured
values from treated and control animals respectively. In both control and treated group the
measured total hemoglobin concentration and blood flow index have positive correlation.
3.3. Evolution of tumor size and hemodynamics
Figure 5 demonstrates the evolution of tumor size and optically-measured hemodynamics in
treated (left column) and control (right column) tumors during the first eighteen days of therapy.
The parameters were measured on the indicated days and are presented with the fitted LOESS
curve and 95% confidence interval for groups of seven treated (T1-T7) and seven control animals
(C1-C7). To investigate the statistical significance of changes within animals in time we have
employed paired t-test between day zero and day eighteen, which corresponds to the period when
no mouse had been sacrificed.
Figure 5 (subplots A and B) shows the measured tumor size by palpation during the term of
therapy. The tumor size in control animals increases rapidly over time and therefore control tumors
have a larger size at day eighteen compared to day zero: 200.0 (165.0- 215.0)%, P = 4×10−4. The
therapy decelerates the tumor growth and the size of treated tumors has increased by 50.0 (25.0-
87.5)%, P = 0.045.
The blood flow index (BFI) of both treated and control animals slowly decreases as shown in
Fig. 5 (subplots C and D). The change of blood flow is statistically significant for both treated
and control animals (P = 0.025 and P = 0.029 respectively) although the change between day
zero and day eighteen is smaller in control animals 4.5 (-12.4- 17.5)% versus 29.6 (20.5- 44.6)%
in treated ones. Moreover, in all treated animals an initial drop of blood flow is observed during
the first week of treatment. On average the blood flow in treated animals has decreased by 42 (37-
56)% after the very first session of therapy (P< 10−4) while no significant change was observed
in controls.
Figure 5 (subplots E and F) shows a gradual decrease of THC in control animals with a
significant change between day zero and day eighteen, 29.6 (20.5- 44.7)% (P = 0.02), while in
treated group there is no significant change in THC (P = 0.9) and the treatment prevents the drop
of THC. Finally, the blood oxygen saturation of the tumor does not have evident fluctuations in
either treated or control animals, Fig. 5 (subplots G and H), although there is a slow decrease
in oxygen saturation over time in control animals, 3.4 (2.2- 5.0)% (P = 0.042). The change in
treated group is statistically insignificant (P = 0.6).
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Fig. 5. Daily changes of tumor size and optically measured hemodynamic parameters during
the first 18 days, which corresponds to the period when no mouse had been sacrificed, for
groups of seven treated (T1-T7) in left column and seven control animals (C1-C7) in right
column. Each marker and error bar represent the value corresponding to average and standard
deviation of measurement over all tumor locations on a specific mouse. The solid line is a
fitted LOESS curve and the gray lines are the 95% confidence intervals. (A, B) represent
tumor sizes measured by palpation, (C, D) blood flow index, (E, F), total hemoglobin
concentration, and (G, H) Oxygen saturation.
3.4. Potential biomarkers to predict the therapy outcome
As shown in Fig. 5, we have measured three hemodynamic parameters during the course of
therapy and as a next step we investigate if there is a feature of them that can be an early indication
of effectiveness of therapy. The antiangiogenic therapy induced significant changes as early as
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four days in blood flow index (P = 8.9×10−4), oxygen saturation (P = 0.029) and borderline
significancy in total hemoglobin concentration (P = 0.051).
However, not all of these indicators are consistent among all treated mice. While every
individual treated tumor has shown a decrease in BFI after the first session of therapy, there is
only a group change in THC and SO2; thus, they cannot predict individual outcome of therapy
although they show a general trend. Therefore, to evaluate the capability of optically measured
parameters to predict the therapeutic outcome, we have studied the correlation between BFI and
conventional parameters, which are standard in oncology labs as identifiers of therapy outcome:
microvessel density and tumor extracted weight. We have excluded the percentage of necrotic
area since this specific therapy does not affect it (Fig. 2).
As it is presented in Fig. 6(A), there is a negative correlation between drop in BFI after the
first session of therapy and the extracted tumor weight (R = -0.77, P = 0.042) and there is no
significant correlation with the microvessel density (P = 0.16). Since in most treated animals the
drop in blood flow continues after the second session of therapy (one week) it might be more
appropriate to consider the maximum blood flow drop in the first week of therapy and its relation
with the therapeutic outcome. The early drop of BFI has a negative correlation with the extracted
tumor weight in treated animals (R = -0.87 and P = 0.001), which suggests the tumors with larger
BFI drop in the first week tend to have lighter extracted tumor Fig. 6(A). There is no significant
early drop of BFI correlation and the microvessel density (P = 0.29).
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Fig. 6. The correlation between early changes of optically measured blood flow and the
extracted tumor weight. (A) Correlation between drop in BFI after the first session of therapy
(day four) and the extracted tumor weight. (B) The correlation between maximum BFI drop
in the first week of therapy and the extracted tumor weight.
4. Discussion
In this study, we have used diffuse optical techniques to monitor the changes in hemodynamics
due to antiangiogenic therapy with DC101, a monoclonal antibody against mouse-VEGFR2 that
is used in preclinical studies. The antibody potently blocks the binding of VEGF to its receptor,
inhibited VEGF-induced signaling, and strongly blocked tumor growth in mouse tumors and
human tumor xenografts through an antiangiogenic mechanism. DC101 binds with high affinity
to vascular endothelial growth factor receptor 2 (VEGFR-2) and blocks the VEGF binding to the
receptor in a dose-dependent manner [71,72]. The dosage and frequency that is used in this study
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is the standard dosage in this type of murine model and have the desired antiangiogenic properties
that can mimic the antiangiogenic therapy in human patients. We have used several advanced
mouse models of renal cell cancer (RCC), human tumorgraft RCC mouse models, designed to
better resemble the human pathology [47, 48, 50]. To investigate the effect of antiangiogenic
therapy in this mouse model, Fig. 2 compares the extracted tumors of treated and control group.
Figure 2(A) shows that the microvessel density in the treated group, 24.6 (14.5- 47.0), is lower
than controls, 62 (55.5- 75.0), and the difference is statistically significant (P = 0.002). This result
is expected since VEGF-targeted therapy blocks further new blood vessel growth.
Figure 2(B) shows that the extracted tumors from the treated animals, 1.9 (1.5- 2.5) g, are
lighter than control ones, 2.7 (2.1- 3.3) g (P = 0.034), which can be explained by considering that
the VEGFR2-blocking antibody slows down the tumor growth. It is worth mentioning once more
that the animals were sacrificed at different time points after the onset of therapy. The sacrificing
for each animal was decided due to the tumor size threshold or mouse weight loss and weakness.
In control animals the enlarged tumor was the the main reason of sacrificing the animal while in
treated group with slower tumor growth they did not reach the tumor size threshold and treated
animals were sacrificed due to weight loss and weakness caused by the therapy.
Figure 2(C) shows that the percentage of tumor necrotic area in treated and control tumors
is respectively 28.7 (28.1- 38.6)% and 40.9 (20.2- 42.8)%. The vascular trimming in treated
animals prevents tumor cells from receiving sufficient nutrition and oxygen expected to cause a
larger necrotic area but we did not observe a significant difference in the tumor necrotic area of
treated and control group (P = 0.8). This might be due to two effects. First, the control mice had
larger tumors when they were sacrificed, which may lead to a larger necrotic area. Second, the
fact that the orthoxenograft tumors derived from a primary biopsy initially responded to DC101
antiangiogenic therapy but eventually the tumors rebounded, i.e. adapted to the treatment with
DC101. When we sacrifice the animals they were in a phase of regrowth, that may be why we did
not observe the expected increase in the necrotic area [11, 49].
We have applied diffuse optical methods to characterize the optical (absorption and scattering
coefficients) as well as physiological properties (blood flow index, total hemoglobin concentration,
and oxygen saturation) of RCC tumors and a healthy control muscle (shoulder). The source-
detector separations that are utilized in this study varies between 1.9 to 5 mm. The penetration
depth has direct relation with the detector distance from the source [27]. As a rule of thumb,
the mean light penetration depth in the reflection geometry is in the order of one half of source-
detector separation (ρ/2), which indicates that our current probe provides information of 2-3
mm deep and allows us to reach the tissue of interest (tumor). In another study [73] with smaller
optode distances (1- 3.5 mm) than our probe, the DCS measurements on superficial murine
tumors under photodynamic therapy (PDT) was validated by comparison with tumor perfusion
measured by power Doppler ultrasound. The two methods detected similar blood flow changes
after PDT. This shows that DCS measurements have been deep enough to sense the blood flow
changes in the tumor. Utilizing larger optode distances in this study ensures the sufficiency of
penetration depth for monitoring of hemodynamic changes due to therapy.
The measured absorption and reduced scattering coefficients (table 1) are in good agreement
with previously reported values for RCC tumors [74]. It been has reported that in RCC tumors
µs
′ (785 nm) ∼ 8 cm−1, which is in agreement with our measurements: µs ′ = 8.5 (7.5- 9.0)
cm−1. Similarly, µa (785 nm) ∼ 0.2 cm−1, which is near to our reported value: µa = 0.19 (0.17-
0.21) cm−1. Table 1 also shows the variability of measurements over different locations for the
pre-treatment values as a measure of tissue heterogeneity. As expected, tissues are heterogeneous
and despite this heterogeneity, we are able to detect changes between different organs and over
time. It is beyond the scope of this paper to investigate the details of this variability..
As shown in Fig. 4, in both control and treated groups, total hemoglobin concentration
(measured by DOS) and blood flow index (measured by DCS) have a positive correlation. The
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correlation coefficients over all days for treated and control groups are respectively R = 0.46
(P = 0.0001) and R = 0.44 (P = 0.0014). The correlation shows that two independent measures
by two independent devices are correlated as expected for this particular condition. Figure 3
compares the measured pre-treatment parameters in RCC tumors and a healthy control tissue
(shoulder muscle). In the tumor the median of blood flow index, 4.5 (4.2 − 6.6) × 10−8 cm2/s,
is higher than healthy shoulder muscle value, 2.3 (2.2- 2.6) ×10−8 cm2/s (P< 10−4) that might
be due to the angiogenesis in the tumor. It is known that RCC tumors are hypervascular due to
the over-expressed VEGF in them [75]. Tumors with over-expressed VEGF have an extended
network of vasculature with higher measure of blood flow [76].
Malignant tumors are usually expected to be hypoxic [18,77]. For instance, the SO2 level in
murine fibrosarcoma was reported to be 36% [73]. It might be due to the enhanced mitochondrial
activity [78], and, could thus, be expected to show a lower oxygen saturation. In contrast, other
types of tumors due to different metabolic mechanisms experience high saturation values, for
instance, mammary adenocarcinoma in rats have SO2 values about 75% [79]. In this study, we
observe that the blood oxygen saturation of the RCC tumor is 75.1 (72.9- 79.2)%, which is
higher than healthy shoulder muscle, 61.5 (58.6- 65.3)% (P< 10−4). One possible contribution to
this is the existence of vascular shunts in RCC tumors, which are the closed arterioles passing
throughout the tumor without having the chance of any oxygen exchange [80]. Furthermore, RCC
tumors rely on glycolysis for their metabolism and due to reduced mitochondrial activity they do
not extract much oxygen from the blood [81, 82]. The rich blood content, which delivers oxygen
and low oxygen extraction would also play a part in the high oxygenation in these tumors.
Figure 5 shows the changes of tumor size and optically-measured hemodynamics over 18
days. In the first row, it is shown that the control tumors grow gradually while therapy decreases
the tumor growth rate. This might be due to the trimming of vasculature in treated animals,
which limits the delivery of oxygen and nutrition needed for the high rate of growth. Moreover,
expression of all VEGFRs has been detected on tumor cells therefore VEGF-targeted therapy may
have direct effects on tumor cells that impair tumor growth in addition to the vascular-trimming
effect [6]. It has also been observed that treated tumors do not grow for one or two weeks and
start to progress afterwards. This is in agreement with previous studies [12–14], where it is
discussed that tumors may transform to an evasive resistance phase after an initially effective
phase of antiangiogenic therapy.
We have observed a significant early reduction in blood flow due to treatment and later recovery
of those parameters (Fig. 5). The observation of early response to the treatment has the potential
to help us in better understanding of the short term efficiency of antiangiogenic therapy. To do so
we need to design studies with larger population. We have also observed a slow decrease in blood
flow over the term of therapy that might be due to tumor growth. As shown in Fig. 6(A), there
is a negative correlation between drop in blood flow index after the first session of therapy and
the extracted tumor weight in treated animals (R = -0.77, P = 0.042). It confirms the previous
findings that blood flow is an important hemodynamic biomarker in cancer studies [83]. Since in
most treated animals the drop in blood flow continues after the second session of therapy (one
week) we have investigated the amount of maximum change in the first week of therapy and its
relation with the therapeutic outcome and we observed more pronounced negative correlation
between the first week drop of blood flow and the extracted tumor weight (R = -0.87 and P = 0.01),
Fig. 6(B). The animals were randomly assigned to the two groups (control and treated) but
showed a difference in pre-treatment hemodynamic parameters. Presumably, this is due to the
small number of animals in each group. To cancel out the pre-treatment condition of tumors, if
we normalize the change of blood flow with respect to the initial value by dividing the blood
flow values by the pre-treatment value, the correlation between early blood flow change and final
tumor weight stays in place (R = 0.8, P = 0.02). There is no significant correlation between early
fluctuations of THC or SO2 and histology values.
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These results suggest that the therapy triggers an early change in blood flow and the amount of
this change is a potential predictor of therapeutic outcome. Similarly, a recent study on murine
tumors [84] suggests that blood flow measured by DCS is a biomarker for therapy outcome
prediction. The study shows that onset of chemotherapy induces early blood flow change, which
correlates with the treatment outcome and can be used to distinguish the treated from untreated
mice individually for effective treatments. Another study that measures blood flow by DCS
during photodynamic therapy in mice tumors [73] shows that the rate of changes of blood flow
strongly correlates with the therapy outcome. Several other studies, which deploy DCS to monitor
blood flow changes induced by therapy in murine tumors, demonstrate the importance of blood
flow monitoring in pre-clinical studies for better understanding the therapy mechanism and to
predict the outcome [85–87]. DCS has also been applied in clinical studies, to monitor blood flow
changes induced by therapy in patients with head and neck cancer [32, 88], breast cancer [28, 31],
and prostate cancer [89]. Our findings on the predictive value of blood flow is coherent with
several other pre-clinical and clinical studies, which suggests that tumor blood flow is a sensitive
parameter to cancer therapy and DCS can measure these flow changes to provide vital information
about therapy mechanism and outcome. However, the main limitation of this exploratory study
is the small number of mice. In the future, to investigate the relation between the blood flow
and therapy outcome and to follow individual variability in a more quantitative manner, we will
increase the study population.
Figure 5(D) shows a gradual decrease of THC (P = 0.02) in control animals while in treated
group (Fig. 5(C)) there is no significant change in THC (P = 0.9). The decrease in THC might
be due to the increased VEGF levels [90, 91] that may cause bone marrow damage and the
anti-VEGF treatment plays a marrow protection role [46] as shown in murine melanoma that
prevents the decrease of THC in treated mice. This needs to be further elaborated in a larger
study.
In Fig. 5, panels G and H show a slow decrease in oxygen saturation over time (between day
zero and 18) in treated and control animals with no significant effect in treated group (P = 0.6) and
significant, 3.4 (2.2- 5.0)% (P = 0.042), in control group. The slight decrease in SO2 might be due
to fast progress of the tumor size, which is more pronounced in control animals. In these cases
the vasculature network does not expand as fast as tumor size and may lead to the necrotic area
with slightly lower oxygen saturation. Moreover, in treated animals the transient normalization of
tumor vessels might produce a temporary enhancement in oxygen delivery [92] that compensates
the effect of tumor growth. To sum up there is no significant difference in oxygen saturation values
between treated and control groups (P = 0.42) at the last day of measurement (before sacrificing).
This demonstrates that although anti-VEGF agents are successful in microvessel trimming, the
collective effect of the treatment does not affect the oxygen saturation in tumors. The similar
necrotic area values in treated and control animals are in agreement with this observation.
Another limitation of this study is the inherent complication of the contact probe, the variations
in probe pressure. This may introduce an artificial variability in the estimated hemodynamic
parameters. To overcome this challenge and to increase the spatial/temporal resolution, we can
deploy non-contact optical elements to scan the tumor surface [93].
To sum up, we have deployed diffuse optical spectroscopy as a noninvasive technique suitable
for repeated measurements to monitor hemodynamic changes during antiangiogenic. These
results demonstrate that diffuse optics is a potential tool to understand the complex mechanism
of VEGFR2-targeted therapy. Furthermore, therapy induced early changes of optically measured
parameters can be used as predictors of the therapy outcome for better prognosis and therapy
planning.
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5. Conclusion
In this study, we have applied diffuse optical spectroscopymethods (DOS andDCS) for monitoring
the hemodynamics of murine renal cell carcinoma (RCC) tumors during antiangiogenic therapy.
DCS provides information of blood flow and DOS measures tissue absorption and scattering as
well as oxygen saturation and total hemoglobin concentration. We have characterized the optical
and physiological properties of RCC tumors by using the complete set of data obtained from the
hybrid DOS/DCS device, where high oxygen saturation in this tumor type was observed.
There is an early response to the induction of antiangiogenic therapy, which triggers a drop in
blood flow after the first session of therapy. The early changes in BFI after the first and second
session of therapy (after three days and one week) correlate with the extracted tumor weight.
These results suggest that diffuse optics is a potential tool to understand the complex mechanism
of antiangiogenic therapy for better therapy planning.
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